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1 Introduction
The treatment of colon cancer by chemotherapy is based 
on drugs that degrade in the stomach, reacting to the 
mechanism of cell division (slowing down or blocking), 
whether being healthy or malignant cells, which causes 
side effects such as allergic reactions, skin disorders, and 
hand-foot syndrome, hair loss.1,2,3
The goal of this this study was to  develop another proce-
dure that would allow the drug to degrade and absorb itself 
only at the level of a diseased organ, such as the colon and 
tumours or metastasis, to reduce the side effects. 
Vectorisation involves transporting an active ingredient 
in sufficient quantity towards the target to be reached by 
means of a vector, soluble or insoluble in water, which is 
inactive from the therapeutic point of view. On the one 
hand this vectorisation makes it possible to avoid direct 
administration of the drug into the human body; on the 
other hand, it allows for improvement of the pharmacoki-
netic characteristics of the active vector ingredient. It is 
then the properties of the vector, and not those of the ac-
tive ingredient, that will determine the fate of the system 
in vivo.4,5,6 Size and shape have gradually emerged as one 
of the major factors influencing the properties of smaller 
drug delivery systems.7
Alginate and chitosan as natural polymers have been re-
tained mainly because they are biodegradable, non-toxic, 
muco-adhesive, and for their good film formation.
They are available in large quantities, and their cost, as well 
as the cost of their gelling and crosslinking agents is low.8,9
Chitosan, a deacetylated derivative of chitin, is a linear 
b (1-4) copolymer of N-acetyl D-glucosamines and D-glu-
cosamines. It is found more rarely in nature: it is present 
only in the wall of a particular class of mushrooms, zygo-
mycetes, and in some insects. Chitin is the most interesting 
source of chitosan.10 It is noted that they all have important 
antioxidant and antimicrobial properties.11
The other biopolymer is alginate, a normal linear pol-
ysaccharide of brown algae. Alginate is a copolymer of 
residues β-D-mannuronate and α-L-guluronate,12 forming 
homo- and heteropolymer blocks. These biopolymers are 
in acidic units of different lengths, sequences, and propor-
tions. Alginate salts differ from most other polysaccharides 
because they have a sol-gel transition if their ionic envi-
ronment is simply changed.13,14 Their antibacterial activity 
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on Escherichia coli, Bacillus subtilis, Staphylococcus aureus, 
and Micrococcus luteus has been studied.15
2 Problematics
Our study aimed to produce a microcapsule vectorised to 
the large intestine where the pH is basic. Therefore, the 
following work criteria was proposed.
2.1 Work criteria
Release in weak acidic medium; release in a strong basic 
medium; release between the two media pH [2–7] is aver-
age; degree of swelling in the basic medium.
3 Materials and methods
3.1 Reagents
Sodium alginate was supplied by Fluka; the viscosity of 2 % 
aqueous solution at 20 °C is greater than 0.3 Pa s.
Chitosan was provided by Fluka, and we deduced the de-
gree of deacetylation (DDA = 78 %).
After examining Table 1, given the different lethal doses 50 
(LD50) depending on the concentration of glutaraldehyde 
in aqueous solutions, we opted for the preparation of an 
aqueous solution of 1 and 2 % by crosslinking.
The other reagents (CaCl2, etc.) were of analytical nature.
3.2 Preparation of microcapsules
The active ingredient was dispersed in a previously pre-
pared solution of sodium alginate (2 %). The suspension 
thus obtained was drained through a needle of a syringe 
into a 2 % CaCl2 solution. Table 2 groups together the dif-
ferent formulations of the microcapsules.
▸ Drying:
Drying in open air at room temperature, under atmospher-
ic pressure and shelter from the light.
In vitro release tests
▸ Apparatus:
The dissolution tests were carried out in a Pharmatest 
PWS300 brand dissolution test apparatus. The device was 
equipped with 6 cylindrical containers with a hemispheri-
cal bottom, one normal capacity of 1000 ml in borosilicate 
glass, equipped with a stirrer consisting of a rod vertical 
Table 2 – Microcapsule formulations
Formulation Procedure
1 [sodium alginate + CaCl2 + active ingredients] non-crosslinked
The active ingredient was dispersed in a previously prepared solution of 
sodium alginate (2 %). The obtained suspension was drained in a solution 
of CaCl2 of 2 %.
2 [sodium alginate + CaCl2 + active ingredients + crosslinking 2 %]
The same experimental protocol as above was adopted by adding 0.7 ml of 
2 % glutaraldehyde (crosslinking agent).
3 [sodium alginate + chitosan solution+ active ingredients + CaCl2 + crosslinking 1 %]
The sodium alginate / active ingredient mixture was stirred for 2 h until a 
homogeneous solution was obtained. Subsequently, it was drained through 
a needle of a syringe into a petri dish, previously containing the chitosan 
solution (2 %), the gelling agent CaCl2 (2 %), and glutaraldehyde (1 %) as 
crosslinking agent.
4 [sodium alginate + chitosan solution + active ingredients + CaCl2 + crosslinking 2 %] The concentration of the crosslinking agent was increased to 2 %.
5
[sodium alginate + chitosan solution + active 
ingredients + CaCl2 + crosslinking 2 %] coated in 
[chitosan solution + crosslinking 2 %]
The microcapsules [sodium alginate + chitosan solution + active 
ingredients + CaCl2 + crosslinking 2 %] already prepared, and well dried, 
were immersed in a 2 % crosslinked chitosan solution.
6
[sodium alginate + chitosan solution + active 
ingredients + CaCl2 + crosslinking 2 %] wet in 
chitosan solution
The formed microcapsules (wet) were immersed directly in a non-
crosslinked chitosan solution in order to ensure the formation of a new 
envelope for the membrane of the microcapsules
7
[sodium alginate + chitosan solution + active 
ingredients + CaCl2 + crosslinking 2 %] dry in 
chitosan solution
We adopted the same experimental protocol. Microcapsules [sodium 
alginate + chitosan solution + active ingredients + CaCl2 + crosslinking 
2 %] were previously dried for 24 h before immersing in the non-
crosslinked chitosan solution
Table 1 – Lethal doses 50 (LD50) for different solutions
Aqueous solution ⁄ % 50 15 5





(a): Oral route for a male rat, (b): Oral route for a male mouse, (c): Oral 
route for a female mouse, (d): Cutaneous route for a male rabbit
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and the lower part of which was fixed to a pallet. Each dis-
solution tank had several orifices allowing the introduction 
of a thermometer. The whole of microcapsules was placed 
in a thermostatted water bath, which maintained the tem-
perature of the dissolution medium.
▸ Preparation of buffer solution similar  
to gastrointestinal pH:
Preparation of pH = 2      0.1 M
Prepare 800 ml of distilled water in a suitable container. 
Add 7.45 g of KCl to the solution. Add 772 mg of HCl to 
the solution. Adjust solution to final desired pH using HCl 
or NaOH. Add distilled water until volume is 1 l.
Preparation of pH = 5      0.1 M
Prepare 800 ml of H2O in a suitable container. Add 1.017 g 
of K2HPO4 to the solution. Add 12.814 g of KH2PO4 to the 
solution. Add H2O until volume is 1 l.
Preparation of pH = 7        0.1 M
Prepare 800 ml of H2O in a suitable container. Add 9.343 g 
of K2HPO4 to the solution. Add 6.309 g of KH2PO4 to the 
solution. Add H2O until volume is 1 l.
Preparation of pH = 8      0.1 M
Prepare 800 ml of H2O in a suitable container. Add 
16.282 g of K2HPO4 to the solution. Add 0.888 g of 
KH2PO4 to the solution. Add H2O until volume is 1 l.
About 40 beads were suspended in the aqueous solutions 
at different pH = 2, 5, 7, and 8, respectively, simulating 
the gastric, physiological, and intestinal media. The sus-
pensions were maintained at a temperature of 37 ± 1 °C, 
and constantly stirred at 100 rpm. The release results were 
determined by UV-Vis spectrophotometry.
3.4 Study of the physical properties 
of the different microcapsules
The physical properties of each of the formulations devel-
oped were determined by estimating the size of the mi-
crocapsules, calculating the encapsulation size, degree of 
porosity, diffusion coefficient, and degree of inflation. This 
study also allowed identification of the best formulation for 
the various microcapsules.
3.4.1 Particle size analysis
The particle size analysis involved 50 microbeads for which 
the mean diameters, called the central value of the micro-
capsule, were calculated using an optical microscope. The 
central value of a microcapsule was calculated from the 
average diameters of the 50 microbeads.






3.4.2 Calculation of encapsulation size
Encapsulation size was estimated for the different systems 
from the LOADING relation, expressed depending on the 
mass of the encapsulated active ingredients and the mass 
of dry particles.
mass of encapsulated active ingredient
mass of dry particles
T = (2)
3.4.3 Porosity
Porosity, P, of the microcapsules was calculated from the 
determination of the amount of water absorbed by the mi-
crocapsules after immersion in the pH = 8 medium.
1 0
1




where m0 is the mass of dry microcapsules, and m1 is the 
mass of wet microcapsules.
3.5 Chemical structural analysis of SC, Alg, and mixture
Chemical characterisation of the SC, Alg, and mixture 
was carried out by FT-IR spectroscopy [SHIMADZU 8400 
(400–4000 cm−1)].
3.6 Microstructure and surface morphology
A scanning electron microscope, Model SEM Quanta 250 
from FEI company was used to study the micro-morpholo-
gy of microcapsules, tested under 12.5–15 kV and 50 mA.
3.7 Statistical parameters
Several statistical parameters can be extracted from the 
PSD such as mode, the median, mean, and variance or 
standard deviation.
3.7.1 PSD classification
The number of peaks (modes): the PSD can be unimodal 
when it has only one peak (one single mode at most) or 
multimodal when it has several peaks or modes represent-
ing a mixture of particles of unimodal distributions.
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3.7.2 Mode
The mode corresponds to the peak of the distribution, i.e. 
the size value for which the PSD is maximal.
3.7.3 Median
The median or size D50 is the size for which the cumula-
tive function is equal to 50 %; similarly, sizes D10 and D90 
are defined by the size values for which the cumulative 
function is equal to 10 % and 90 %, respectively.
3.7.4 Standard deviation
The standard deviation measures the width of the distribu-
tion around its mean. The standard deviation is the square 
root of the variance of PSD.
3.7.5 Coefficient of variation (CV)
The ratio between the standard deviation and the mean 
diameter defines the coefficient of variation (CV).
4 Results and discussion
In vitro diffusion studies 
4.1 Effect of crosslinking agent on the release of sodium 
alginate-based microcapsules
Examination of Table 3a shows that the release rate of 
the active ingredient is important during the first 3 h in 
different pH media. Beyond this period, a decrease was 
observed in the size of the microcapsules until their to-
tal disappearance. This phenomenon could be due to the 
erosion of microcapsules.
The works of Fabian Nussbaum16 on encapsulation by so-
dium alginate showed that microcapsules based on algi-
nate are characterised by a smooth surface. His work16 on 
encapsulation with sodium alginate showed that alginate 
microcapsules are characterised by a smooth and ridged 
surface. These striations are due to deep breaks in the mi-
crocapsules.
Moreover, Payet et al.17 have also shown that this type of 
microcapsule is unstable and rapidly degrades in an acid-
ic or basic medium. The results of Payet showed that the 
release of active ingredients for such microcapsules or na-
noparticles was impossible, and that alginate degradation 
occurred in the presence of Na+ ions as soon as the ratio 
of Na+/Ca++ was sufficiently high. All these observations 
corroborate our results.
Bhattarai’s research18 has shown that glutaraldehyde 
crosslinks with alginate. The crosslinking is between the 
carbonyl groups of the aldehyde function of glutaralde-
hyde and the hydroxyl functions of the alginate.
Table 3b suggests that the release rate of the active ingredi-
ent was less important than in the case of non-crosslinked 
microcapsules (Formulation 1). The disappearance of the 
microcapsules (Formulation 2) occurred only starting from 
the sixth hour. The addition of the crosslinking agent had 
strengthened the membrane of the microcapsules pro-
duced in this study.
However, it is important to note that the behaviour of 
active ingredients’ release failed to follow the criteria es-
tablished in this study; namely, a low release in acid and 
neutral medium and, very important, in basic medium. For 
this purpose, we combined sodium alginate and chitosan 
in a new formulation of microcapsules.





1 2 3 4 5 6
pH = 2 14.9 15.2 25.8
Reduction in the size 
of the particle until 
disappearance 
pH = 5 13.7 15.9 23.2
pH = 7 12.2 16 31.1




1 2 3 4 5 6
pH = 2 10.7 11.3 16.1 24.9 35.6 –
pH = 5 10.4 12.0 15.5 22.7 32.2 –
pH = 7 11.4 12.7 14.2 26.4 34.1 –
pH = 8 19.8 26.5 29.2 33.9 36.3 –
4.2 Effect of chitosan and crosslinking 
concentration on microcapsule release
Adopted were five formulations for the preparation of this 
type of microcapsule (sodium alginate / chitosan solution 
/ active ingredients) crosslinking by varying the concentra-
tion of the crosslinking agent, the coating procedure (mon-
olayer, double layer, coating in dry and wet states).
Uragami et al.19 showed that, in the presence of sodi-
um alginate and chitosan, glutaraldehyde preferentially 
crosslinks with chitosan.
The concentration of the crosslinking agent influences the 
phenomenon of active ingredients release. The low lev-
el was observed after the addition of 2 % of crosslinking 
agent, (Fig. 1b). Microcapsules crosslinked with 2 % gluta-
raldehyde left their active ingredients diffused in a smaller 
quantity in acidic media compared to the microcapsules 
(Formulation 3) crosslinked at 1 %, (Fig. 1a). The increase 
in crosslinking agent concentration would therefore gen-
erate good rigidity of the microcapsules (Formulation 4).
Nevertheless, the values of active ingredient concentra-
tions remain relatively high in the acid and neutral media 
(pH = 2, 5, and 7), and in order to minimise the release 
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rate of active ingredients in the acidic medium, in the next 
step, the membrane microcapsules were reinforced with a 
new layer of crosslinked chitosan.
The work of Y. Song et al.20 also confirms the influence of 
the level of crosslinking of a chitosan membrane on sol-
ubility (degradation). This decreases with an increase in 
concentration of crosslinking agent. In general, when the 
membranes are crosslinked, the selectivity of the mem-
brane is increased but the release rate is decreased. This 
confirms our results; the lowest release rate was obtained 
after adding 2 % of crosslinking agent.
In addition, the 2 % crosslinked microcapsules are stable, 
resistant, and give higher active ingredients release rates 
than those crosslinked with 1 % glutaraldehyde whatever 
the pH of the medium. However, such results do not co-
incide with our work criteria, and it is mainly for this rea-
son that we prepared another type of microcapsule coated 
with chitosan that can give rise to better resistance of the 
microcapsules in acidic medium.
4.3 Influence of coating on release kinetics
In this part, three procedures were followed. In general, 
the release rate of active ingredient microcapsules coat-
ed with crosslinked chitosan (Formulation 5) still remained 
high in acidic medium. It increased considerably, and sta-
bilised after 3 h in a neutral environment (Fig. 2a). In basic 
medium, the release rate increased continuously with a 
medium release rate.
Formulation 6 showed a better release of active ingredi-
ents for different pH media compared to the other systems 
(Fig. 2b). The important result obtained was that in basic 
medium, the rate of release increased considerably and 
rapidly upon contact with the medium pH = 8.
Fig. 1 – a) Release evolution of the microcapsules (F3) as a func-
tion of time for the different pH media (1 % crosslink-
ing); b) release evolution of the microcapsules (F4) 
as a function of time for the different pH media (2 % 
crosslinking)
Fig. 2 – a) Evolution of Formulation 5 release as a function of time for different pH media; b) release 
evolution of wet microcapsules (Formulation 6) in SC as a function of time for different pH 
media; c) evolution of release of dry microcapsules (Formulation 7) in SC as a function of time 
for different pH media
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This phenomenon can be explained by an inflation of the 
microcapsules, which was followed by a large and rapid 
diffusion across the membrane [sodium alginate/crosslink-
ing (2 %)] chitosan solution.
The plots in (Fig. 2c) (Formulation 7), suggest that the de-
crease in the thickness of the membranes caused an in-
crease in the flux of permeability to the basic medium 
(34.5 μg ml−1) at the sixth hour better than Formulation 6 
(24.2 μg ml−1). Formulation 7 best meets the criteria estab-
lished in this work. In fact, the release of the active ingredi-
ents was slow with a low release rate for acid (0.71 μg ml−1) 
and neutral (1.9 μg ml−1) medium at the first hour, whereas 
in basic medium, the microcapsules swelled remarkably, 
by inducing a faster release and a much larger release rate.
4.4 Study of the physical properties 
of the different microcapsules
The microcapsules obtained were spherical (reservoir sys-
tem), with an average diameter equivalent to 800 microns. 
The study of the release of active ingredients from the dif-
ferent formulations, in pH = 2, 5, 7, and 8 media, showed 
no deformation or size change of the microcapsules, ex-
cept in the case of microcapsules coated with chitosan. In 
basic medium, they showed significant swelling.
In order to estimate the rate of swelling, the different mi-
crocapsules were weighed in their dry and wet state (after 
having immersed them in solution at pH = 8 for 6 h), and 
their initial and final masses were determined. The results 
in Table 4 confirm the swelling of dry or wet microcapsules 
coated with chitosan by increasing the mass of the latter. 
According to particle size analysis, the average size of the 
microcapsules was approximately 820 μm and of spheri-
cal shape (reservoir system) (Fig. 3), with an encapsulation 
size estimated at T = 40. The calculation of the porosity 
showed that the dry and wet microcapsules coated with 
chitosan were the most porous, 69 %, thus generating the 
highest release rate (results are shown in Table 5).
Fig. 3 – Microscopic image of empty microcapsule at 40× mag-
nification
4.5 Chemical structural analysis of SC, Alg, and mixture
The FT-IR spectra of chitosan (SC), sodium alginate (Alg), 
and their mixture of polyelectrolytes (ACH) are shown in 
(Fig. 4). The spectrum of (SC) shows a wide and intense 
band centred at approximately 3409.9 cm−1 and corre-
sponds to the stretching vibrations due to the overlap of 
the OH and NH bonds. The peaks observed at 2881 and 
2144.7 cm−1 are due to symmetrical or asymmetrical CH2 
stretching vibrations of the pyranose ring. The characteris-
tic absorption bands of chitosan are generally observed be-
tween 1654.8 cm−1 and 1596.9 cm−1, which corresponds 
to stretching of C−O (amide I) and bending of N−H (amide 
II), respectively. The absorption bands at 1080.1 cm−1 and 
1029.9 cm−1 (skeletal vibrations involving C−O stretching) 
are characteristic of the structure of the polysaccharide. Al-
ginate absorption bands near 1635.5 and 1419.6 cm−1 are 
associated with the asymmetric and symmetrical stretching 
vibrations of the carboxylate anions, respectively, as oth-
ers have observed. The spectrum of sodium alginate also 
shows a strong and wide band at 3444.6 cm−1 linked to the 
O−H stretch, and a weak band of aliphatic C−H stretch 
at 2927.7 cm−1. Due to its polysaccharide structure, bands 
of approximately 1245.9 cm−1 (C−O stretch), 1038.8 cm−1 
(C−O−C stretch) were observed. In FT-IR spectra of mixed 
oppositely charged polysaccharides, we observed changes 
in the placement and disappearance of certain bands or the 
appearance of new peaks compared to a single alginate or 
chitosan. The complexed material has a narrower and more 
intense band at around 3409.9 cm−1, which is caused by 
the formation of new hydrogen bonds between the −OH 
and −NH2 groups of chitosan and the −C=O and −OH 
groups of the sodium alginate. Bands attributed to move-
ments of the carboxylate salt group were invisible after com-
plexation. This disappearance was due to the lower content 
of excess alginate and chitosan in all ACH composites.
The possible shifts towards the shorter wavelengths and the 
widening of the vibration bands of the functional groups in-
volved, could account for the presence of specific interac-
Table 4 – Variation of swelling of microcapsules in medium 
pH = 8






Table 5 – Variation of porosity of microcapsules in medium 
pH = 8
Formulation Initial mass ⁄ g Final mass ⁄ g Porosity ⁄ %
3 0.0016 0.0018 11.11
4 0.0016 0.0017 5.8
5 0.0019 0.0022 13.63
6 0.0018 0.0051 64.70
7 0.0017 0.0055 69
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tions likely to develop. A shift can be seen from the 1654.8 







































Fig. 4 – FT-IR spectra of chitosan (a), sodium alginate (b), and 
mixed (Alg/ SC) systems (c)
4.6 Kinetics of diffusion
The diffusion kinetics of microcapsules in different media 
were studied. For this purpose, calculated the diffusion co-
efficient was calculated using Fick’s law applied to short 
times from the slope of the plot (mt/m∞) depending on √t.
The kinetics of diffusion of the formulation microcapsules 
(Formulation 7) in the different pH media is illustrated in 
Fig. 5. The values of the diffusion coefficients are summa-
rised in Table 6.
As may be seen from Table 6, a decrease occurred in the 
values of the diffusion coefficient of active ingredients in 
acid medium, particularly in the case of dry sodium algi-
nate microcapsules coated with non-crosslinked chitosan. 
In the pH = 5 medium, the diffusion coefficient for this 
same formulation was still lower than those determined for 
the other forms. While in the neutral medium, the values 
of the diffusion coefficients were practically similar. This 
would be mainly due to the pH of the interior of the micro-
capsule, which would be the same as that of the external 
medium (pH = 7). In basic medium (pH = 8), the diffusion 
coefficients of the different microcapsules varied between 
0.4 and 0.54, thus inducing an extension of the release 
time of the active ingredients.
Table 6 – Diffusion coefficients apparent at short times of differ-
ent forms and at different pH
Formulation pH
2 5 7 8
3 Di/ro2 0.25 0.54 0.29 0.54
4 Di/ro2 0.52 0.35 0.77 0.47
5 Di/ro2 0.54 0.6 0.37 0.26
6 Di/ro2 0.39 0.68 0.34 0.52
7 Di/ro2 0.11 0.33 0.36 0.42
Once again, these results confirmed that Formulation 7 
was that which best met the work criteria of this study. 
In fact, with this formulation, the lowest release of active 
ingredients was obtained in acid and neutral media, and a 
majority release in the medium at pH = 8 corresponding 
to the pH of the colon.
Many parameters, such as pH, degree of acetylation, crys-
tallinity, and porosity influence the final degree of swelling. 
Studies have shown that a decrease occurs in the crystal-
linity of non-crosslinked chitosan; therefore, the molecules 
of the aqueous medium penetrate into the amorphous re-
gions more easily than into crystalline regions. In addition, 
swellability is greater for strong acetylation degrees.
The microcapsules of the formula dried for 24 h were thin-
ner, which influenced the permeability or even the diffusion 
of molecules of the aqueous medium penetrating through 
the pores of the membrane causing the microcapsules to 
inflate, which was larger for those with a smaller diame-
ter than those with a larger diameter. According to the lit-
erature, it has been shown that a decrease in membrane 
thickness leads to an increase in permeability flow, which 
Fig. 5 – Variation of the ratio (mt/m∞) according to √t for micro-
capsules of Formulation 7 dry in SC
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confirms the findings of this study. Therefore, the fifth for-
mula was the closest to what this study aimed to produce.
In addition, calculation of diffusion coefficients for differ-
ent pHs showed that the formula had the smallest coeffi-
cient in an acid medium, neutral and suitable for pH = 8 
medium, reflected by the low rate of release in different 
environments where pH varied from (2, 5, and 7), and dif-
fusion in large quantities for pH = 8. Thus, Formulation 7 
was the closest to what this study aimed to produce.
4.7 In vitro tests of dry microcapsules coated with 
chitosan in a medium similar to the gastrointestinal 
tract
Fourty microcapsules of the fifth formulation were placed 
in a gelatine capsule (in order to preserve their quantity 
during passage through the digestive tract). The evolution 
of the microcapsules was then monitored in solutions at 
pH = 2.7 and 8, simulating the passage of microcapsules 
in the gastrointestinal environment. The microcapsules 
were immersed for 2 h (average time) in each pH. The 
results obtained are grouped in Table 7.
It was found that for acid and neutral media, the release 
rate remained relatively low, not exceeding 23 %. In the 
basic medium (corresponding to colon pH), the release 
rate was 67 %. The microcapsules also underwent a re-
markable swelling, causing complete degradation after the 
sixth hour.
Table 7 – In vitro tests of the chosen formula
pH 2 7 8
duration ⁄ h 2 2 2
concentration ⁄ µg ml−1 2.65 6.65 26.8
release rate ⁄ % 6.7 16.5 67
4.8 Statistical parameters
The particle size distribution involved fifty microbeads (for-
mulation F7) for which the diameter of the microcapsule 
was calculated using an optical microscope.
Particle size distribution (PSD) of the microcapsules of F7 
formulation containing active ingredient is shown in Fig. 6. 
The PSD was unimodal, with sizes ranging from 750 µm 
to 900 µm. The mean diameter in frequency was 816 μm 
and D(50) was 800 μm. The current unimodal PSD is con-
sidered suitable for the application of microcapsules in the 
pharmaceutical field.21
Table 8 groups the main statistical parameters for the mi-
crocapsules of the seventh formulation chosen.
Table 8 – PSD statistical parameters












⁄ µm CV ⁄ %
800 750 850 38.39 800 816 4.70
The coefficient of variation was less than 15 %, so the par-
ticle size values were homogeneous.
4.9 Microstructure and surface morphology
All the microcapsules (Fig. 7) were of spherical shape and 
fairly rough surface, with numerous undulations on the 
outer surface, which increases the surface area. This is a 
beneficial quality because a higher surface area allows bet-
ter mass transfer.
(a) (b)
Fig. 7 – (a) Complete image of the microcapsule (formulation 
F7), and (b) a view of its surface
cumulative particle size distribution
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Fig. 6 – Particle size distribution
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(a) (b)
Fig. 8 – SEM images of the microspheres (a), and of the ampli-
fied surface of a microsphere (b)
Fig. 8 presents a scanning electron microscopy image of the 
surface of microcapsules coated with a layer of crosslinked 
chitosan (Formulation 7) and the amplified surface of a mi-
crocapsule. Pores of 900 nm to 5 µm were present on the 
surface.
Fig. 9 – Surface of the crosslinked chitosan shell material
The enlarged SEM of the microcapsules (formulation F7) 
(Fig. 9) shows the surface of the crosslinked chitosan shell 
material. The reaction of the crosslinked chitosan at the 
interface of the microcapsules formed the shell of the cap-
sule, and the surface of the microcapsules gradually be-
came coarse and covered with granular deposits as the 
reaction proceeded. The rough surface resulted from the 
deposition and SC.
The synthesised microcapsules were analysed by SEM. 
Fig. 10 shows that the microcapsule was composed of a 
rough outer surface and a second wall of the microcap-
sule [sodium alginate + chitosan solution + active ingre-
dients + CaCl2 + crosslinking 2 %] with a relatively po-
rous. Cross-section of the capsule wall revealed that the 
thickness of the outer shell was approximately 13 µm. The 
structure of the envelope of the synthesised microcapsules 
was in good agreement with those described in other pub-
lications.
5 Conclusion
This study, concerning the variation of the release rate of 
the active ingredients as a function of the pH, time, and 
diffusion coefficient calculation of formulas in different 
pH media, shows that the crosslinking of microcapsule 
matrices of chitosan-alginate systems with glutaraldehyde 
controls the release of active ingredients depending on 
the desired medium (pH). This control was improved by 
changing the microporous morphological structure of the 
microcapsules from the coating. The dry [sodium alginate 
/ chitosan solution / active ingredients + crosslinking 2 %] 
formulation coated with non-crosslinked chitosan, Formu-
lation 7, was the standard formula to target colon diseases, 
which met all the work criteria of this study, with a core 
release rate of 67 %. According to the SEM analysis and the 
parameters obtained from PSD, the structure of the enve-
lope of the synthesised microcapsules is in good agreement 
with those described in other publications.
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Fig. 10 – (a) Cross-section of the capsule wall, (b) space between 
the layers
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SAŽETAK
Optimizacija mikrokapsulacije aktivnog sastojka umrežavanjem i 
metodom premazivanja za liječenje bolesti debelog crijeva
Mounir Hammoudi,a* Djamel Atsamnia,b Khaled Otmanine,c  
Riadh Moumen b i Mustapha Oumouna a
Cilj ove studije bio je pripremiti mikrokapsule na bazi prirodne polimerne otopine kitozana (viso-
kog stupnja deacetiliranja (DDA), niske molekulske mase (MW) i niske viskoznosti)/natrijeva algi-
nata u prisutnosti umreženog agensa (glutaraldehida), za inkapsuliranje i vektoriziranje aktivnog 
sastojka prema bolesnom organu (debelom crijevu), bez difuzije u druge razine probavnog trakta, 
kako bi se povećala terapijska učinkovitost liječenja kemoterapijom i smanjili neželjeni učinci. 
Metoda pripreme mikrokapsula dobivenih iz sustava natrijeva alginata/otopine kitozana/aktivnih 
sastojaka ispitana je uobičajenom optičkom mikroskopijom. Uz to, provedeno je istraživanje in 
vitro na profilima oslobađanja aktivnih sastojaka, ovisno o pH koji simulira želučani i crijevni 
medij za sedam predloženih sustava. Treba napomenuti da je u osnovnom mediju (pH(debelog 
crijeva) = 8) oslobađanje aktivnih sastojaka od najveće važnosti. Ipak, kontrola tog ispuštanja 
može se poboljšati sredstvom za umrežavanje i metodom premazivanja. Suha formulacija [oto-
pina natrijeva alginata/kitozana/aktivnih sastojaka + umreženog 2 %] presvučena neumreženim 
kitozanom (formulacija 7) standardna je formula koja udovoljava svim kriterijima iz našeg ranijeg 
rada s brzinom otpuštanja jezgre od 67 %. PSD je bio unimodalan s veličinama koje su se kretale 
od 750 µm do 900 µm.
Ključne riječi 
Mikrokapsule, bolesti debelog crijeva, alginat, kitozan, vektorizacija, oblaganje, umrežavanje 
